LFG
CRVS icon

Larson Financial Group’s Corvus Pharmaceuticals CRVS Stock Holding History

Larson Financial Group’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.03K Buy
69
+4
+6% +$56 ﹤0.01% 3303
2026
Q1 		$951 Buy
+65
New +$1.04K ﹤0.01% 3176

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Larson Financial Group's CRVS Position: Q2 2026 in Review

Larson Financial Group increased its Corvus Pharmaceuticals (CRVS) stake by 6.2% in Q2 2026, buying an estimated $56 and bringing the position to 69 shares worth $1.03K. The position accounts for ﹤0.01% of the portfolio, ranked #3303.

Larson Financial Group first reported a position in CRVS in Q1 2026 and has held it in 2 quarters since. 173 funds tracked by Wall St. Rank hold CRVS as of Q2 2026.

  • Larson Financial Group held 69 shares of Corvus Pharmaceuticals worth $1.03K as of Q2 2026.
  • Larson Financial Group bought 4 Corvus Pharmaceuticals shares in Q2 2026, an estimated $56.
  • Corvus Pharmaceuticals made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #3303 holding.
  • Larson Financial Group first reported a position in Corvus Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 173 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.